All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Since CAR-T therapy has achieved great success in adoptive immunotherapy of relapse/refractory cancer, many efforts have been taken to improve the safety, effectiveness, and persistence of the cells to treat complex solid tumors. Recently, a multi-target CAR technology has been developed to direct constant CAR-engineered immune cells toward multiple tumors or targets. This functional CAR is designed by introducing a modified NKG2D (mNKG2D) extracellular domain as a ligand-binding domain to the scFV location of a classic CAR molecular. The mNKG2D-CAR expressing cells are activated by the modified NKG2D ligand fused to antigen-specific antibodies and then attracted to the tumor site and perform antigen-specific cytotoxicity. The mNKG2D-mediated CAR-cell therapy is versatile and flexible under the regulation of different antibodies.
Fig.1 NKG2D on NK and T cells mediated cytotoxicity. (Slavuljica, et al., 2021)
With extensive knowledge and experience in immunotherapy development, Creative Biolabs offers CAR-T, CAR-NK, CAR-MA, and TCR-T products and development services for global clients. Using the robust immune cell engineering platform, we present modified NKG2D-based multi-target CAR as an attractive universal CAR candidate.
We provide multiple downstream services to assess the potency of established CAR constructs.
Interested in our Smart™ CAR construction services? Please send an email to contact us and let our experienced experts accelerate your subject.
Creative Biolabs offers classical CAR vectors design, first through fifth generation, and customized smart CAR design services.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION